Lidemol Special Precautions

Prolonged use of topical corticosteroid products may produce atrophy of the skin. When used on the face, this may occur even with short term use.
Significant systemic absorption may result when corticosteroids are applied over large areas of the body, even when occlusion is not used.
Administration of topical corticosteroids to children should be limited to a short period of time and to the smallest amount compatible with an effective therapeutic regimen.
These preparations are not intended for ophthalmic use.
Topical corticosteroids should be used with caution on lesions close to the eye.
Occlusive dressing increases the percutaneous absorption of topical corticosteroids. Its use can be helpful in the treatment of recalcitrant dermatoses. Tight-fitting diapers or plastic pants on a child may also function as an occlusive dressing and increase absorption of topical corticosteroids by the underlying skin.
Patients (particularly children) receiving a large dose of topical corticosteroid applied to a large surface area or under an occlusive dressing should be evaluated for evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression. If HPA axis suppression is noted, the dose should be reduced or gradually discontinued.
In the presence of an infection, the use of an appropriate antibacterial, antiviral or antifungal agent should be instituted. If a favourable response does not occur promptly, Fluocinonide (Lidemol) 500 mcg/g (0.05%) Cream should be discontinued until the infection has been adequately controlled.
Use in Pregnancy: See USE IN PREGNANCY & LACTATION section for further information.